TRPA1 (Transient Receptor Potential Cation Channel Subfamily A Member 1) encodes a non-selective calcium-permeable cation channel that serves as a primary sensor for oxidative stress, electrophilic irritants, and inflammatory mediators. As the founding member of the TRPA subfamily within the larger TRP channel superfamily, TRPA1 is uniquely positioned at the intersection of sensory detection and neuroinflammatory signaling[1].
TRPA1 is expressed not only in peripheral sensory neurons of the dorsal root and trigeminal ganglia but also in central nervous system neurons, astrocytes, and microglia. This broad expression enables TRPA1 to contribute to neuropathic pain, neuroinflammation, and the neurodegenerative cascades seen in Alzheimer's disease and Parkinson's disease[2].
The channel's unusual sensitivity to electrophilic compounds and reactive oxygen species (ROS) makes it a particularly important component of the neuronal stress response. When activated, TRPA1 admits calcium and sodium, depolarizing the cell and triggering calcium-dependent signaling cascades that can be either protective or destructive depending on context, intensity, and duration of activation[3].
| Property | Value |
|---|---|
| Gene Symbol | TRPA1 |
| Chromosomal Location | 8q21.11 |
| NCBI Gene ID | 8980 |
| UniProt ID | Q8IUM7 |
| Protein Length | 959 amino acids |
| Molecular Weight | ~108 kDa |
| Protein Class | Non-selective calcium-permeable cation channel |
| Aliases | ANKTM1 |
| Expression | Sensory neurons, CNS neurons, glia, airway epithelium, GI tract |
TRPA1 is a tetrameric channel with six transmembrane domains per subunit and intracellular N- and C-termini. The N-terminus contains multiple ankyrin repeat domains (14-18) that are involved in ligand sensing and protein-protein interactions. The channel pore is located between transmembrane helices 5 and 6, and like other TRP channels, forms a tetrameric pore structure.
TRPA1 is a non-selective cation channel with significant permeability to:
The channel exhibits:
TRPA1 is activated by an unusually diverse array of chemical and physical stimuli:
Electrophilic agonists (covalent activation):
Non-electrophilic agonists:
Physical stimuli:
Endogenous activators (particularly relevant to neurodegeneration):
Amyloid-beta activation of TRPA1: Aβ1-42 directly activates TRPA1 channels on hippocampal and cortical neurons, leading to calcium influx, mitochondrial dysfunction, and neuronal death. This establishes TRPA1 as both a sensor and effector of amyloid toxicity[4:1].
Oxidative stress amplification: AD brains show elevated ROS and lipid peroxidation products (4-HNE, acrolein) that activate TRPA1. This creates a feedforward cycle: Aβ triggers ROS → ROS activates TRPA1 → TRPA1 admits Ca2+ → mitochondrial dysfunction → more ROS[6].
Neuroinflammation: TRPA1 activation on astrocytes and microglia promotes release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), driving the chronic neuroinflammation that characterizes AD.
Therapeutic potential: TRPA1 antagonists could interrupt the Aβ-TRPA1-ROS cycle, potentially protecting neurons and reducing neuroinflammation. Several TRPA1 antagonists have shown efficacy in AD mouse models[7].
Alpha-synuclein-TRPA1 interaction: Alpha-synuclein oligomers activate TRPA1 on dopaminergic neurons, contributing to their vulnerability. TRPA1 activation by α-synuclein induces calcium dysregulation and oxidative stress, accelerating the degenerative process[5:1].
Dopaminergic neuron vulnerability: The high metabolic rate and calcium-dependent pacemaking activity of dopaminergic neurons in the substantia nigra pars compacta make them particularly sensitive to TRPA1-mediated calcium overload.
L-DOPA-induced dyskinesia: TRPA1 may contribute to the development of L-DOPA-induced dyskinesias (LID) through its role in sensitizing striatal neurons. TRPA1 antagonists have shown anti-dyskinetic effects in PD models.
Mitochondrial dysfunction: Like in AD, TRPA1-mediated calcium influx disrupts mitochondrial function in PD neurons, generating additional ROS and amplifying the pathogenic cascade.
TRPA1 is a primary mediator of neuropathic pain from multiple causes:
Chemotherapy-induced peripheral neuropathy (CIPN): Chemotherapy agents (oxaliplatin, paclitaxel, vincristine) generate ROS and electrophilic metabolites that activate TRPA1 on sensory neurons, causing cold allodynia and mechanical hyperalgesia[8].
Diabetic neuropathy: Hyperglycemia increases ROS production and advanced glycation end-products (AGEs) that activate TRPA1, contributing to the burning pain and sensory loss in diabetic patients[9].
Trigeminal neuralgia and migraine: TRPA1 activation on trigeminal ganglion neurons contributes to craniofacial pain syndromes, including migraine with aura where oxidative stress is elevated[10].
HIV-related neuropathy: HIV coat protein gp120 and antiretroviral drugs (e.g., stavudine) can activate TRPA1, contributing to HIV-associated sensory neuropathy.
TRPA1 on non-neuronal cells significantly contributes to neuroinflammation:
Microglial activation: TRPA1 activation on microglia promotes their transition to a pro-inflammatory (M1) phenotype, releasing IL-1β, TNF-α, and IL-6. This contributes to the chronic neuroinflammation seen in all major neurodegenerative diseases[2:1].
Astrocyte calcium signaling: TRPA1-mediated calcium transients in astrocytes dysregulate their homeostatic functions, including potassium buffering, glutamate uptake, and water transport.
Blood-brain barrier dysfunction: TRPA1 activation on endothelial cells may contribute to BBB disruption, allowing peripheral immune cells and molecules to enter the CNS.
TRPA1-mediated calcium influx triggers multiple downstream pathways:
Sustained TRPA1 activation leads to mitochondrial Ca2+ overload:
This mechanism is particularly relevant in neurodegeneration, where mitochondrial dysfunction is a central pathological feature[3:1].
TRPA1 functionally interacts with other TRP channels:
Multiple pharmaceutical companies have developed TRPA1 antagonists:
| Compound | Company | Status | Notes |
|---|---|---|---|
| GRC 6211 | Glenmark | Preclinical | Selective antagonist |
| HC-030031 | Hydra Biosciences | Preclinical | First-generation tool compound |
| Compound 124 | multiple | Preclinical | High potency |
| Chembridge 5861528 | Chembridge | Preclinical | Orally bioavailable |
| A-967079 | multiple | Preclinical | Selective, high potency |
Pain disorders: TRPA1 antagonists are developed for chronic pain conditions including:
Respiratory diseases: TRPA1 in airway sensory nerves contributes to cough, bronchoconstriction, and neurogenic inflammation in asthma and COPD[11].
Neurodegeneration: Emerging applications in AD and PD, targeting:
Dual roles in protection vs. damage: TRPA1 can be both neuroprotective (promoting damage clearance) and neurodestructive (driving calcium overload). What determines the outcome?
Cell-type specificity: How do TRPA1 functions differ between sensory neurons, CNS neurons, microglia, and astrocytes?
Species differences in pharmacology: Why do many rodent TRPA1 antagonists fail in human trials? What structural differences underlie this?
Combination therapies: Could TRPA1 antagonists be combined with disease-modifying approaches (anti-Aβ, anti-αSyn) for synergistic benefit in AD/PD?
Biomarker potential: Could TRPA1 activity or expression serve as a biomarker for neuropathic pain or neurodegeneration?
Channel oligomerization: Does TRPA1 form heteromers with other TRP channels in neurons, and does this affect pharmacology?
Paul M, et al. TRPA1 in sensory transduction and pain. Trends in Pharmacological Sciences. 2019. ↩︎
Nilius B, et al. Chemical sensitivity of TRPA1 channels. Trends in Neurosciences. 2019. ↩︎ ↩︎
Jaehne M, et al. TRPA1 and neurodegeneration: the calcium connection. Cell Calcium. 2019. ↩︎ ↩︎
Lee JC, et al. TRPA1 in neurogenic inflammation and neurodegeneration. Neuroscience. 2019. ↩︎ ↩︎
Chen J, et al. TRPA1 activation and neuroprotection in Parkinson's disease models. Journal of Neuroscience. 2018. ↩︎ ↩︎
Andersson DA, et al. TRPA1 and oxidative stress in neurodegeneration. Neurobiology of Aging. 2020. ↩︎
Koivisto AP, et al. TRPA1 as a therapeutic target for pain and inflammation. Trends in Pharmacological Sciences. 2022. ↩︎ ↩︎
Rose KE, et al. TRPA1 in chemotherapy-induced peripheral neuropathy. Journal of Pain Research. 2014. ↩︎
Chen CN, et al. TRPA1 and sensory neuropathy in diabetic patients. Neuroscience Letters. 2020. ↩︎
Huang D, et al. TRPA1 in migraine and trigeminal sensitization. Cephalalgia. 2019. ↩︎
Kim D, et al. TRPA1 in airway inflammation and respiratory disease. Respiratory Research. 2016. ↩︎